TScan Therapeutics (NASDAQ:TCRX) Earns “Outperform” Rating from Wedbush

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report sent to investors on Wednesday, RTT News reports. They currently have a $10.00 price objective on the stock. Wedbush also issued estimates for TScan Therapeutics’ Q1 2024 earnings at ($0.27) EPS, Q2 2024 earnings at ($0.23) EPS, Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.98) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.08) EPS, FY2026 earnings at ($1.13) EPS and FY2027 earnings at ($0.91) EPS.

Separately, HC Wainwright reissued a buy rating and issued a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday, March 7th.

TScan Therapeutics Trading Down 1.4 %

Shares of NASDAQ TCRX opened at $6.82 on Wednesday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.18. The business has a fifty day simple moving average of $7.06 and a two-hundred day simple moving average of $5.67. The firm has a market cap of $326.54 million, a PE ratio of -3.61 and a beta of 0.90. TScan Therapeutics has a twelve month low of $1.62 and a twelve month high of $9.00.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. The business had revenue of $7.21 million during the quarter, compared to analyst estimates of $2.94 million. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. Analysts expect that TScan Therapeutics will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC purchased a new position in TScan Therapeutics during the 4th quarter worth $31,000. Jane Street Group LLC purchased a new position in TScan Therapeutics during the 2nd quarter worth $32,000. Renaissance Technologies LLC purchased a new position in TScan Therapeutics during the 1st quarter worth $37,000. Pale Fire Capital SE purchased a new position in TScan Therapeutics during the 3rd quarter worth $42,000. Finally, American Century Companies Inc. purchased a new position in TScan Therapeutics during the 3rd quarter worth $49,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.